JP2025506374A - インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物 - Google Patents

インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物 Download PDF

Info

Publication number
JP2025506374A
JP2025506374A JP2024545861A JP2024545861A JP2025506374A JP 2025506374 A JP2025506374 A JP 2025506374A JP 2024545861 A JP2024545861 A JP 2024545861A JP 2024545861 A JP2024545861 A JP 2024545861A JP 2025506374 A JP2025506374 A JP 2025506374A
Authority
JP
Japan
Prior art keywords
composition
compound
formula
amount
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506374A5 (cg-RX-API-DMAC7.html
Inventor
ブロックス,ジェラルディン
ティー. ブレスリン,デービッド
アンドゥイ カント,クララ
ドベラーレ,クリストファー ポール デ
デニアウ,ジルダス
プレトロ,ジウスティーノ ディ
フェルナンデス,フィリッペ
コラコヴィッチ,ルジカ
メルテンス,ナタリー
ロマスタイン ペデルセン,ベティー
ラジャン,ゴーパル
サン,ダジュン
パテル,セジャル
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2025506374A publication Critical patent/JP2025506374A/ja
Publication of JP2025506374A5 publication Critical patent/JP2025506374A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024545861A 2022-02-01 2023-01-31 インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物 Pending JP2025506374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305631P 2022-02-01 2022-02-01
US63/305,631 2022-02-01
PCT/US2023/061651 WO2023150500A1 (en) 2022-02-01 2023-01-31 Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JP2025506374A true JP2025506374A (ja) 2025-03-11
JP2025506374A5 JP2025506374A5 (cg-RX-API-DMAC7.html) 2026-02-26

Family

ID=85556753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545861A Pending JP2025506374A (ja) 2022-02-01 2023-01-31 インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物

Country Status (13)

Country Link
EP (1) EP4472999A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506374A (cg-RX-API-DMAC7.html)
KR (1) KR20240137102A (cg-RX-API-DMAC7.html)
CN (1) CN118829647A (cg-RX-API-DMAC7.html)
AU (1) AU2023215245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250172A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002263A1 (cg-RX-API-DMAC7.html)
IL (1) IL314629A (cg-RX-API-DMAC7.html)
MX (1) MX2024009477A (cg-RX-API-DMAC7.html)
PE (1) PE20241895A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342496A (cg-RX-API-DMAC7.html)
UY (1) UY40135A (cg-RX-API-DMAC7.html)
WO (1) WO2023150500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250139359A (ko) 2023-01-31 2025-09-23 얀센 파마슈티카 엔브이 인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
EP4780453A1 (en) * 2023-09-21 2026-07-29 Janssen Pharmaceutica NV Interleukin-23 receptor antagonist for use in the treatment of ulcerative colitis
WO2025151385A1 (en) * 2024-01-08 2025-07-17 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor and uses thereof
WO2025163534A1 (en) * 2024-01-31 2025-08-07 Janssen Pharmaceutica Nv Crystal form of a peptide inhibitor of interleukin-23 receptor
WO2025243217A1 (en) * 2024-05-22 2025-11-27 Janssen Pharmaceutica Nv Crystal forms of peptide molecules
WO2026106852A1 (en) * 2024-11-15 2026-05-21 Janssen Pharmaceutica Nv Methods of using interleukin-23 receptor antagonists
WO2026114760A1 (en) * 2024-11-29 2026-06-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie

Also Published As

Publication number Publication date
UY40135A (es) 2023-08-31
KR20240137102A (ko) 2024-09-19
WO2023150500A1 (en) 2023-08-10
CN118829647A (zh) 2024-10-22
AU2023215245A1 (en) 2024-09-19
MX2024009477A (es) 2024-11-08
TW202342496A (zh) 2023-11-01
PE20241895A1 (es) 2024-09-19
CL2024002263A1 (es) 2025-02-07
EP4472999A1 (en) 2024-12-11
CA3250172A1 (en) 2023-08-10
IL314629A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
KR20240137102A (ko) 인터류킨-23 수용체의 펩티드 억제제 및 이의 약제학적 조성물
US11939361B2 (en) Compositions of peptide inhibitors of Interleukin-23 receptor
AU2011290614B2 (en) Nalbuphine-based formulations and uses thereof
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2008064202A2 (en) Modified-release formulations of calcium receptor-active compounds
KR102197465B1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
CN103717223A (zh) 含甘磷酸胆碱或者其药学上可接受的盐的缓释药物组合物及其制造方法
KR20260029301A (ko) 골수성 키놈 억제제의 고체 분산물 및 그를 포함하는 제약 조성물
WO2020175897A1 (ko) 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제
WO2022180582A1 (en) Oral pharmaceutical composition of arsenic trioxide
KR20230002361A (ko) 카파 오피오이드 수용체 효능제의 올리고당 제형
JP2026505072A (ja) インターロイキン-23受容体の結晶性ペプチド阻害剤を調製するための方法
JP2814513B2 (ja) 溶出性の改良された製剤組成物
HK40117634A (en) Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof
HK40131057A (en) Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
TW201924661A (zh) 含有非馬沙坦的固體分散體
WO2025163534A1 (en) Crystal form of a peptide inhibitor of interleukin-23 receptor
HK40092077A (en) Compositions of peptide inhibitors of interleukin-23 receptor
EA051796B1 (ru) Композиции пептидных ингибиторов рецептора интерлейкина-23
JP5044572B2 (ja) イミダゾリルアルキル−ピリジンの安定な投薬製剤
KR20150137272A (ko) 안정한 프레가발린 제어 방출성 서방형 제약 조성물 및 그 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260202